HF
EUCRU

HRT Financial’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

HRT Financial’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,385
Closed -$114K – 3527
2022
Q3 		$114K Hold
11,385
– – ﹤0.01% 2366
2022
Q2 		$114K Hold
11,385
– – ﹤0.01% 2403
2022
Q1 		$112K Hold
11,385
– – ﹤0.01% 2632
2021
Q4 		$113K Hold
11,385
– – ﹤0.01% 2727
2021
Q3 		$113K Hold
11,385
– – ﹤0.01% 2865
2021
Q2 		$116K Hold
11,385
– – ﹤0.01% 2559
2021
Q1 		$115K Hold
11,385
– – ﹤0.01% 2441
2020
Q4 		$121K Buy
+11,385
New +$116K ﹤0.01% 1607

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

HRT Financial's EUCRU Position: Q4 2022 in Review

HRT Financial sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 11,385 shares — an estimated $114K sold.

HRT Financial first reported a position in EUCRU in Q4 2020 and held it in 8 quarters. The position peaked at $121K in Q4 2020. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

  • HRT Financial reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
  • HRT Financial sold 11,385 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $114K.
  • HRT Financial first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 8 quarters.
  • HRT Financial's Eucrates Biomedical Acquisition Corp. Unit position peaked at $121K in Q4 2020.
  • 6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on HRT Financial's 13F filing for Q4 2022, filed 10 Feb 2023.